vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and TIDEWATER INC (TDW). Click either name above to swap in a different company.
TIDEWATER INC is the larger business by last-quarter revenue ($336.8M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). TIDEWATER INC runs the higher net margin — 65.3% vs 11.1%, a 54.2% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -2.4%). TIDEWATER INC produced more free cash flow last quarter ($147.8M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Tidewater, Inc. is a publicly traded international petroleum service company headquartered in Houston, Texas, U.S. It operates a fleet of ships, primarily providing vessels and marine services to the offshore petroleum and offshore wind industries.
ANIP vs TDW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $336.8M |
| Net Profit | $27.5M | $219.9M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 19.0% |
| Net Margin | 11.1% | 65.3% |
| Revenue YoY | 29.6% | -2.4% |
| Net Profit YoY | 367.5% | 495.8% |
| EPS (diluted) | $1.14 | $4.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $336.8M | ||
| Q3 25 | $227.8M | $341.1M | ||
| Q2 25 | $211.4M | $341.4M | ||
| Q1 25 | $197.1M | $333.4M | ||
| Q4 24 | $190.6M | $345.1M | ||
| Q3 24 | $148.3M | $340.4M | ||
| Q2 24 | $138.0M | $339.2M | ||
| Q1 24 | $137.4M | $321.2M |
| Q4 25 | $27.5M | $219.9M | ||
| Q3 25 | $26.6M | $-806.0K | ||
| Q2 25 | $8.5M | $72.9M | ||
| Q1 25 | $15.7M | $42.7M | ||
| Q4 24 | $-10.3M | $36.9M | ||
| Q3 24 | $-24.2M | $46.4M | ||
| Q2 24 | $-2.3M | $50.4M | ||
| Q1 24 | $18.2M | $47.0M |
| Q4 25 | 14.1% | 19.0% | ||
| Q3 25 | 15.9% | 18.4% | ||
| Q2 25 | 6.6% | 23.7% | ||
| Q1 25 | 13.3% | 22.5% | ||
| Q4 24 | -2.3% | 23.6% | ||
| Q3 24 | -13.8% | 20.6% | ||
| Q2 24 | 3.7% | 23.0% | ||
| Q1 24 | 14.8% | 25.5% |
| Q4 25 | 11.1% | 65.3% | ||
| Q3 25 | 11.7% | -0.2% | ||
| Q2 25 | 4.0% | 21.4% | ||
| Q1 25 | 8.0% | 12.8% | ||
| Q4 24 | -5.4% | 10.7% | ||
| Q3 24 | -16.3% | 13.6% | ||
| Q2 24 | -1.7% | 14.8% | ||
| Q1 24 | 13.2% | 14.6% |
| Q4 25 | $1.14 | $4.37 | ||
| Q3 25 | $1.13 | $-0.02 | ||
| Q2 25 | $0.36 | $1.46 | ||
| Q1 25 | $0.69 | $0.83 | ||
| Q4 24 | $-0.45 | $0.70 | ||
| Q3 24 | $-1.27 | $0.87 | ||
| Q2 24 | $-0.14 | $0.94 | ||
| Q1 24 | $0.82 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $578.8M |
| Total DebtLower is stronger | — | $670.1M |
| Stockholders' EquityBook value | $540.7M | $1.4B |
| Total Assets | $1.4B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $578.8M | ||
| Q3 25 | $262.6M | $428.2M | ||
| Q2 25 | $217.8M | $369.4M | ||
| Q1 25 | $149.8M | $341.8M | ||
| Q4 24 | $144.9M | $324.9M | ||
| Q3 24 | $145.0M | $280.8M | ||
| Q2 24 | $240.1M | $315.9M | ||
| Q1 24 | $228.6M | $280.9M |
| Q4 25 | — | $670.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $647.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $1.4B | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $1.1B | ||
| Q2 24 | $455.8M | $1.1B | ||
| Q1 24 | $452.0M | $1.1B |
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $920.8M | $2.1B | ||
| Q1 24 | $914.5M | $2.1B |
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $153.0M |
| Free Cash FlowOCF − Capex | $29.1M | $147.8M |
| FCF MarginFCF / Revenue | 11.8% | 43.9% |
| Capex IntensityCapex / Revenue | 0.5% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.70× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $353.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $153.0M | ||
| Q3 25 | $44.1M | $54.7M | ||
| Q2 25 | $75.8M | $85.4M | ||
| Q1 25 | $35.0M | $86.0M | ||
| Q4 24 | $15.9M | $100.0M | ||
| Q3 24 | $12.5M | $49.0M | ||
| Q2 24 | $17.4M | $78.6M | ||
| Q1 24 | $18.3M | $54.8M |
| Q4 25 | $29.1M | $147.8M | ||
| Q3 25 | $38.0M | $49.6M | ||
| Q2 25 | $71.8M | $80.2M | ||
| Q1 25 | $32.5M | $75.7M | ||
| Q4 24 | $13.5M | $95.5M | ||
| Q3 24 | $7.7M | $43.3M | ||
| Q2 24 | $13.0M | $72.3M | ||
| Q1 24 | $13.7M | $43.8M |
| Q4 25 | 11.8% | 43.9% | ||
| Q3 25 | 16.7% | 14.5% | ||
| Q2 25 | 34.0% | 23.5% | ||
| Q1 25 | 16.5% | 22.7% | ||
| Q4 24 | 7.1% | 27.7% | ||
| Q3 24 | 5.2% | 12.7% | ||
| Q2 24 | 9.4% | 21.3% | ||
| Q1 24 | 10.0% | 13.6% |
| Q4 25 | 0.5% | 1.5% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 1.3% | 3.1% | ||
| Q4 24 | 1.3% | 1.3% | ||
| Q3 24 | 3.2% | 1.7% | ||
| Q2 24 | 3.2% | 1.9% | ||
| Q1 24 | 3.3% | 3.4% |
| Q4 25 | 1.10× | 0.70× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.17× | ||
| Q1 25 | 2.23× | 2.02× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 1.06× | ||
| Q2 24 | — | 1.56× | ||
| Q1 24 | 1.00× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TDW
Segment breakdown not available.
